These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


198 related items for PubMed ID: 10773591

  • 1. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy.
    Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, Gamwell Henriksen E, Qvist P, Alexandersen P, Bang Henriksen D.
    Bone; 2000 May; 26(5):505-11. PubMed ID: 10773591
    [Abstract] [Full Text] [Related]

  • 2. Markers of bone resorption--measurement in serum, plasma or urine?
    Huber F, Traber L, Roth HJ, Heckel V, Schmidt-Gayk H.
    Clin Lab; 2003 May; 49(5-6):203-7. PubMed ID: 15285175
    [Abstract] [Full Text] [Related]

  • 3. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
    Okabe R, Inaba M, Nakatsuka K, Miki T, Naka H, Moriguchi A, Nishizawa Y.
    J Bone Miner Metab; 2004 May; 22(2):127-31. PubMed ID: 14999523
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT.
    Rosen HN, Parker RA, Greenspan SL, Iloputaife ID, Bookman L, Chapin D, Perlmutter I, Kessel B, Qvist P, Rosenblatt M.
    Calcif Tissue Int; 2004 May; 74(5):415-23. PubMed ID: 14961215
    [Abstract] [Full Text] [Related]

  • 5. Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy.
    Peris P, Alvarez L, Monegal A, Guañabens N, Durán M, Echevarría M, Ros I, Ballesta AM, Muñoz-Gómez J.
    J Bone Miner Metab; 2002 May; 20(2):116-20. PubMed ID: 11862534
    [Abstract] [Full Text] [Related]

  • 6. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
    Alexandersen P, Peris P, Guañabens N, Byrjalsen I, Alvarez L, Solberg H, Cloos PA.
    J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
    [Abstract] [Full Text] [Related]

  • 7. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study.
    Garnero P, Mulleman D, Munoz F, Sornay-Rendu E, Delmas PD.
    J Bone Miner Res; 2003 Oct; 18(10):1789-94. PubMed ID: 14584889
    [Abstract] [Full Text] [Related]

  • 8. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 9. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides.
    Christgau S, Rosenquist C, Alexandersen P, Bjarnason NH, Ravn P, Fledelius C, Herling C, Qvist P, Christiansen C.
    Clin Chem; 1998 Nov; 44(11):2290-300. PubMed ID: 9799756
    [Abstract] [Full Text] [Related]

  • 10. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
    Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC.
    Osteoporos Int; 2000 Nov; 11(4):295-303. PubMed ID: 10928218
    [Abstract] [Full Text] [Related]

  • 11. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 12. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.
    Ascott-Evans BH, Guanabens N, Kivinen S, Stuckey BG, Magaril CH, Vandormael K, Stych B, Melton ME.
    Arch Intern Med; 2003 Apr 14; 163(7):789-94. PubMed ID: 12695269
    [Abstract] [Full Text] [Related]

  • 13. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
    Wiernikowski JT, Barr RD, Webber C, Guo CY, Wright M, Atkinson SA.
    J Oncol Pharm Pract; 2005 Jun 14; 11(2):51-6. PubMed ID: 16460605
    [Abstract] [Full Text] [Related]

  • 14. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women.
    Greenspan SL, Rosen HN, Parker RA.
    J Clin Endocrinol Metab; 2000 Oct 14; 85(10):3537-40. PubMed ID: 11061497
    [Abstract] [Full Text] [Related]

  • 15. Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
    Zikan V, Stepan JJ.
    Bone; 2009 Apr 14; 44(4):634-8. PubMed ID: 19150421
    [Abstract] [Full Text] [Related]

  • 16. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T.
    Ann Rheum Dis; 2008 Mar 14; 67(3):353-7. PubMed ID: 17644538
    [Abstract] [Full Text] [Related]

  • 17. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A.
    Ann Acad Med Stetin; 2003 Mar 14; 49():111-30. PubMed ID: 15552843
    [Abstract] [Full Text] [Related]

  • 18. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harpe K.
    Zhonghua Yi Xue Za Zhi; 2004 Feb 17; 84(4):269-73. PubMed ID: 15059505
    [Abstract] [Full Text] [Related]

  • 19. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
    Muñoz-Torres M, Reyes-García R, Mezquita-Raya P, Fernández-García D, Alonso G, Luna Jde D, Ruiz-Requena ME, Escobar-Jiménez F.
    Maturitas; 2009 Nov 20; 64(3):188-92. PubMed ID: 19819089
    [Abstract] [Full Text] [Related]

  • 20. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
    Trento LK, Pietropolli A, Ticconi C, Gravotta E, De Martino MU, Fabbri A, Piccione E.
    J Obstet Gynaecol Res; 2009 Feb 20; 35(1):152-9. PubMed ID: 19215563
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 10.